Details of the Drug Combination

General Information of Drug Combination (ID: DCSL2S0)

Drug Combination Name

Physostigmine Scopolamine

Indication

Disease Entry	Status	REF
Nicotine dependence	Discontinued	[1]

Component Drugs

Physostigmine DM2N0TO

Scopolamine DMOM8AL

Small molecular drug

2D MOL

3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Indication(s) of Physostigmine

Disease Entry	ICD 11	Status	REF
Xerostomia	DA02.1	Discontinued in Phase 2	[2]

Physostigmine Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Acetylcholinesterase (AChE)	TT1RS9F	ACES_HUMAN	Inhibitor	[5]
------------------------------------------------------------------------------------

Physostigmine Interacts with 1 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Cocaine esterase (CES2)	OTC647SQ	EST2_HUMAN	Decreases Activity	[6]
------------------------------------------------------------------------------------

Indication(s) of Scopolamine

Disease Entry	ICD 11	Status	REF
Addictive disorder	6C50-6C5Z	Approved	[3]
Allergic rhinitis	CA08.0	Approved	[4]
Common cold	CA00	Approved	[4]
Cough	MD12	Approved	[4]
Irritable bowel syndrome	DD91.0	Approved	[4]
Major depressive disorder	6A70.3	Approved	[4]
Mydriasis	LA11.62	Approved	[4]
Nausea	MD90	Approved	[3]
Peptic ulcer	DA61	Approved	[4]
Vasomotor/allergic rhinitis	CA08	Approved	[4]
Iridocyclitis	N.A.	Investigative	[4]
Uveitis	9A96.Z	Investigative	[4]

Scopolamine Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Muscarinic acetylcholine receptor (CHRM)	TTOXS3C	NOUNIPROTAC	Antagonist	[7]
------------------------------------------------------------------------------------

Scopolamine Interacts with 2 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Microtubule-associated protein 2 (MAP2)	OT6UYT3X	MTAP2_HUMAN	Decreases Expression	[8]
Neurofilament heavy polypeptide (NEFH)	OTMSCW5I	NFH_HUMAN	Decreases Expression	[8]
------------------------------------------------------------------------------------

References

1	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006543)
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6598).
3	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 330).
4	Scopolamine FDA Label
5	The effects of physostigmine on acetylcholinesterase activity of CSF plasma and brain. A comparison of intravenous and intraventricular administration in beagle dogs. Neuropharmacology. 1986 Oct;25(10):1167-77.
6	Purification and cloning of a broad substrate specificity human liver carboxylesterase that catalyzes the hydrolysis of cocaine and heroin. J Biol Chem. 1997 Jun 6;272(23):14769-75. doi: 10.1074/jbc.272.23.14769.
7	The amygdala modulates morphine-induced state-dependent memory retrieval via muscarinic acetylcholine receptors. Neuroscience. 2009 May 5;160(2):255-63.
8	Protective role of Ashwagandha leaf extract and its component withanone on scopolamine-induced changes in the brain and brain-derived cells. PLoS One. 2011;6(11):e27265. doi: 10.1371/journal.pone.0027265. Epub 2011 Nov 11.